Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Real-time Quote. Real-time Tradegate - 08/16 07:15:40 pm
82.374 EUR   +0.74%
10:27a SANOFI : Regeneron drops RSV drug
10:26a LEXICON PHARMAC : With an eye on the FDA, Lexicon and Sanofi line up..
08/14 SANOFI : Publishes Its First Integrated Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

SANOFI : PRESS RELEASE : Former Research Chemist At Global Pharmaceutical Company Sentenced To 18 Months In Prison For Theft Of Trade Secrets

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2012 | 07:17pm CEST

United States Attorney

District of New Jersey

FOR IMMEDIATE RELEASE CONTACT: Rebekah Carmichael

May 7, 2012 Office of Public Affairs

www.justice.gov/usao/nj (973) 645-2888

FORMER RESEARCH CHEMIST AT GLOBAL PHARMACEUTICAL COMPANY

SENTENCED TO 18 MONTHS IN PRISON FOR THEFT OF TRADE SECRETS

TRENTON, N.J. - A former research chemist with global pharmaceutical company

sanofi-aventis ("sanofi") was sentenced today to 18 months in prison for stealing sanofi's trade

secrets and making them available for sale through Abby Pharmatech, Inc. ("Abby"), the U.S.

subsidiary of a Chinese chemicals company, U.S. Attorney Paul J. Fishman announced.

Yuan Li, 30, of Somerset, N.J., a Chinese national, previously pleaded guilty to an

Information charging her with one count of theft of trade secrets. Li entered her guilty plea

before U.S. District Judge Joel A. Pisano, who also imposed the sentence today in Trenton

federal court.

According to documents filed in this case and statements made in court:

Sanofi is a global healthcare company with U.S. headquarters in Bridgewater, N.J.

Among other things, sanofi is engaged in the development, manufacture and marketing of

healthcare products including the prescription drugs Allegra, Plavix, Copaxone and Ambien.

Li worked as a research scientist at sanofi's Bridgewater headquarters from October 2006

through June 2011, where she directly assisted in the development of a number of compounds

that sanofi viewed as potential building blocks for future drugs. These compounds were sanofi's

trade secrets and had not been disclosed outside of sanofi in any manner, including by means of a

patent application.

While employed at sanofi, Li was also a 50 percent partner in Abby, which is engaged in

the sale and distribution of pharmaceuticals.

Li admitted that between January 2010 and June 2011, she accessed an internal sanofi

database and downloaded information related to a number of sanofi compounds, including their

chemical structures, onto her sanofi-issued laptop computer. She also admitted she then

transferred the information to her personal home computer by sending it to her personal e-mail

address or via a USB thumb drive.

Li acknowledged that she made the stolen compounds available for sale on Abby's

website.

In addition to the prison term, Judge Pisano sentenced Li to serve two years of supervised

release and ordered her to pay $131,000 in restitution.

U.S. Attorney Fishman credited special agents of the FBI, under the direction of Special

Agent in Charge Michael B. Ward, with the investigation.

The government is represented by Assistant U.S. Attorney Gurbir S. Grewal of the

Computer Hacking and Intellectual Property Section of the U.S. Attorney's Office Economic

Crimes Unit in Newark.

12-159 ###

Defense counsel: Paul Brickfield Esq., River Edge, N.J.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
10:27a SANOFI : Regeneron drops RSV drug
10:26a LEXICON PHARMACEUTICALS : With an eye on the FDA, Lexicon and Sanofi line up mor..
08/14 SANOFI : Publishes Its First Integrated Report
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11 SANOFI : Disclosure of trading in own shares
08/11 SANOFI : Disclosure of trading in own shares
08/10 LEXICON PHARMACEUTICALS : Announces Opt-In Decision For U.S. Co-Promotion Of Sot..
08/10 NOVO NORDISK A/S : may drop US insulin price as Sanofi suffers
08/10 Roche out-licenses lebrikizumab rights to Dermira
08/09 SANOFI : Files Suit in the U.S. to Defend its Patent Rights on Lantus
More news
News from SeekingAlpha
08/15 Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q2 2017 Update
08/14 Fibrogen And Galapagos Raise Lung Disease Hopes
08/11 MyoKardia's Strong Secondary Offering Flashes A Buy Signal
08/11 SANOFI'S ZIKA STANDOFF : Bad Medicine?
08/10 Looking Beyond Factors In Hemophilia
Financials (€)
Sales 2017 36 335 M
EBIT 2017 9 499 M
Net income 2017 7 865 M
Debt 2017 4 807 M
Yield 2017 3,73%
P/E ratio 2017 13,28
P/E ratio 2018 17,21
EV / Sales 2017 2,97x
EV / Sales 2018 2,88x
Capitalization 103 231 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 86,0 €
Spread / Average Target 5,2%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI6.33%121 184
JOHNSON & JOHNSON15.77%357 992
NOVARTIS9.99%219 731
ROCHE HOLDING LTD.5.07%217 452
PFIZER2.77%198 782
MERCK AND COMPANY6.17%170 460